argenx - GO for Sjögren's
*Based on Ph2 RHO study data, ARGX decided to advance Efgar into Ph3 development for Sjögren's. Data detail will be shared at an upcoming conference.*Remember that RHO was meant to be a signal-finding study (vs. dose-finding for J&J's Ph2 with competitor anti-FcRn Nipo which enrolled > 160 pts), hence only a limited number of patients were enrolled not making the primary endpoint powered for statistical significance. IR confirmed, however, that strong improvements were seen for the composite primary endpoint, and its individual components, as well as for relevant biomarker measurements such as autoantibody and immune complex reductions.*Now that cPoC isArgenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.